Enduro Genetics presented synthetic biology innovations enabling enhanced monoclonal antibody production by engineering cellular pathways to counteract micro-evolution-induced productivity loss in biomanufacturing. This approach leverages biosensors and genetic promoters responsive to production burden, optimizing cell populations for sustained high output. The technology offers a novel method to improve biologics manufacturing efficiency, critical to meeting rising therapeutic demand while controlling costs.